A novel cystic fibrosis mutation “delS1255” in a male diagnosed at birth

Cystic fibrosis (CF) is an autosomal recessive disorder caused by pathogenic variants in the CFTR gene. Over 2000 CFTR variants have been identified, and ongoing genetic characterization remains critical for guiding eligibility for CFTR modulator therapies and contributing to variant databases that support diagnosis and research. We describe a 20-year-old Caucasian male who is a compound heterozygous for the common F508del mutation and a novel variant, p.Ser1255del (c.3763_3765delTCA; delS1255). He was diagnosed with CF in the neonatal period following meconium ileus, confirmed by elevated sweat chloride testing. His clinical course included pancreatic insufficiency, chronic Staphylococcus aureus colonization, and sinus disease with nasal polyps, but no evidence of CF-related diabetes or liver disease. Molecular diagnostic testing conducted at Stanford Clinical Laboratory using PCR and bidirectional Sanger sequencing confirmed the F508del mutation and identified the previously unreported delS1255 variant, an in-frame deletion of a serine residue at position 1255. This variant is absent from population databases and a missense mutation at the same codon has previously been associated with severe CF phenotypes, supporting its likely pathogenicity. The patient was initiated on elexacaftor-tezacaftor-ivacaftor (ETI) therapy in 2021, based on the presence of the F508del allele. Since starting ETI, he has experienced substantial clinical improvement, including improved spirometry, radiology, and a marked reduction in sweat chloride concentration. The response is presumed to be driven by the F508del variant, while the effect of delS1255 on modulator responsiveness remains unknown. This case adds to the growing spectrum of CFTR variants with clinical relevance. • Identifies a previously unreported CFTR variant, p.Ser1255del • Describes the clinical features of a patient with F508del and delS1255 • Highlights diagnostic confirmation by sweat testing and gene sequencing • Explores the patient’s clinical response to modulator therapy • Contributes to expanding the known spectrum of CFTR variants

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.